rVSV S GP/VP40

Drug Profile

rVSV S GP/VP40

Alternative Names: BPSC-1001; Ebola vaccine - Merck & Co; Ebola virus vaccine - NewLink Genetics; Public Health Agency of Canada's Ebola vaccine; rVSV delta G ZEBOV GP; rVSV-EBOV; rVSV-S-GP/VP40; rVSV-ZEBOV; rVSV-ZEBOV-GP; rVSVΔG-ZEBOV-GP; V-920; VSV delta G ZEBOV; VSV delta-ZEBOV; VSV-EBOV; VSV-ZEBOV; VSVG-ZEBOV

Latest Information Update: 28 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Public Health Agency of Canada
  • Developer Canadian Immunization Research Network; Centers for Disease Control and Prevention; Dalhousie University; Merck & Co; National Institute of Allergy and Infectious Diseases; NewLink Genetics Corporation; Norwegian Institute of Public Health; University of Oxford; VEBCON Consortium
  • Class Synthetic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Ebola virus infections

Most Recent Events

  • 28 May 2018 No recent reports of development identified for phase-I development in Ebola-virus-infections(Prevention) in Gabon (IM, Injection)
  • 28 Jan 2018 No recent reports of development identified for phase-I development in Ebola-virus-infections in Kenya (IM, Injection)
  • 28 Dec 2017 No recent reports of development identified for phase-I development in Ebola-virus-infections(In volunteers) in Germany (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top